Skip to main content

Table 6 Twenty-one patients with positive anti-ds-DNA Abs after IFX

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

  

anti-DNA

ANA

    
 

age/sex

before

after

before

after

EULAR response

symptoms

IFX

following biologics

1

51/F

< 2

300

40

320

No

 

Discontinue

ADA- > TOC*4

2

41/F

6

300

320

320

No

 

Discontinue

ETN

3

45/F

51

300

160

320

No

SLE like*1

Discontinue

ETN

4

32/F

NA

52

320

1280

No

   

5

31/F

5

42

80

160

No

SLE like*2

Discontinue

ETN

6

36/F

5

38

40

1280

No- > good

 

PSL 20 mg iv*3

 

7

43/F

4

26

160

640

No

 

Discontinue

TOC

8

56/F

3

26

80

160

No- > good

 

PSL 20 mg iv*3

 

9

62/M

21

25

80

80

Good

PCP

Discontinue

TOC

10

65/F

2

23

160

160

No

 

Discontinue

TOC- > ETN*5

11

52/F

NA

22

NA

160

No

   

12

56/M

< 2

20

320

320

No

allergy

Discontinue

ETN

13

33/F

5

19

40

80

No

   

14

51/F

< 2

13

40

80

Mod

   

15

56/M

< 2

11

160

160

No- > mod

 

PSL 20 mg iv*3

 

16

75/F

< 2

11

< 40

320

No

 

Discontinue

ETN

17

58/F

11

11

80

640

Mod

   

18

30/M

< 2

10

80

80

No

 

Discontinue

ETN

19

35/F

< 2

10

80

80

Good

   

20

40/F

3

8

80

160

No

 

Discontinue

ETN

21

59/F

NA

7

NA

640

Mod

   
  1. anti-DNA, anti-ds-DNA antibodies; ANA, antinuclear antibodies; IFX, infliximab; SLE, systemic lupus erythematosus; PCP; pneumocystis jirovecii pneumonia; PSL, prednisolone; iv, intravenous injection; ADA, adalimumab; ETN, etanercept; TOC, tocilizumab; *1, leukocytopenia and alopecia; *2, erythema; *3, premedication of each IFX administration; *4, ADA was also getting no response and successful swiched to TOC; *5, TOC ineffective, and ETN effective
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us